Introduction {#s1}
============

HIV remains a major global public health issue, having claimed more than 35 million lives so far. In 2017, 940,000 people died from HIV-related causes globally ([@B20]). The active anti-retroviral therapies are efficient and have saved many lives but still present multiple caveats: need for high compliance, permanent treatment, and unwanted side effects and complications ([@B41]). Developing alternative and simple solutions such as immunoprophylactic or immunotherapeutic options remains a public health priority. In line with this, a better understanding of the molecular etiology of disease progression is essential.

Due to the impact of the disease in the Western world, HIV research has been the subject of intense efforts for the past 35 years and has helped in promoting several new research technologies, in particular with high-throughput studies from the "omics" era.

In this review, we will present large-scale studies based on various technologies that have been undertaken to tackle HIV molecular etiology and their main results. These large-scale studies encompass mainly genomics with genome-wide association studies (GWASs) based on genotyping chips and with exome sequencing, transcriptomic studies from SIV and HIV patient cells, and small interfering RNA (siRNA) studies in sensitive cell lines. We will also briefly describe the results obtained from proteomics and epigenomics screenings.

A Short Recall on HIV-1 Infection and Markers {#s2}
=============================================

There are three successive stages in HIV infection: the acute primary infection, the asymptomatic stage and symptomatic HIV infection, and acquired immunodeficiency syndrome (AIDS). Depending on the individual, AIDS, the most advanced stage of the infection course, can occur within a few months to several years after HIV infection, with an average of around 8 years in the Western world. This stage has been defined by the Center for Disease Control (CDC) either as a drop of CD4 T-cell count below 200/mm^3^ or as the appearance of opportunistic infections or some cancers ([@B7]). Quite early, AIDS cohorts were enrolled and prospectively followed, and it became apparent that this infection was exhibiting a considerable phenotypic heterogeneity at different levels: virus acquisition, disease progression, viral load control, and response to treatment ([@B38]; [@B47]; [@B17]; [@B57]; [@B23]; [@B48]; [@B66]). For instance, some individuals, called long-term non-progressors, are infected but never progress to AIDS; the elite controllers have never exhibited any detectable viral load; and the rapid progressors reach the AIDS stage within a few months following their infection. This phenotypic variability may be attributed to a complex interplay between viral, environmental, and host genetic factors that could be investigated through several types of large-scale studies or omics.

If the CD4 cell count was the major marker to follow HIV-1 infection and immune deficiency in patients in the early 1980s, the progress of molecular biology techniques has made it possible to measure precisely HIV-1 viral load in the blood (i.e., the number of viral particles present in each ml of serum) by the late 1990s. Together with the CD4 cell count, this marker has become very useful to evaluate the status of an infected patient, either a low viral load suggesting a good control of HIV-1 infection or a high viral load suggesting a progressive infection at an early stage of infection or an uncontrolled infection at a late disease stage (AIDS). Most cohorts focus on viral load outcomes (e.g., viral control, viral load at set point), but (slow and rapid) progression phenotypes have also been defined based on the CD4 counts (e.g., the GRIV cohort).

Genetic Association Studies {#s3}
===========================

Host genes associated with various phenotypes have been extensively explored since the mid-1990s. The concept is as follows: if a particular phenotype (for instance, elite control) is statistically associated with the presence or absence of a genetic variant, the corresponding gene or its product may be involved in the molecular mechanisms of viral infection/dissemination. Genetic association studies can thus provide new clues on the molecular mechanisms of infection and disease progression and, in the long run, identify new targets for the development of new therapeutic or diagnostic strategies. Initial studies have focused on candidate genes such as *HLA* ([@B32]; [@B6]; [@B21]), and a large number of host genetic associations with HIV outcomes have been identified. The main confirmed association was a 32-base-pair deletion in the *CCR5* gene (*CCR5-Δ32*) ([@B10]; [@B46]; [@B68]; [@B64]), but other variants closely located in the *CCR5* promoter ([@B49]; [@B50]) or in the nearby *CCR2* gene ([@B70]) were also influential. This deletion led to the expression of a truncated and non-functional cell surface CCR5 protein that happened to be the major HIV-1 entry co-receptor ([@B1]; [@B11]; [@B46]). Other candidate gene studies pointed to immunity-related genes (e.g., *KIR*, *IL10*, *IFNγ*) and genes encoding HIV restriction factors (e.g., *CCL5*, *APOBEC3G*, *CUL5*) but were only partially replicated according to the phenotype and cohort tested. The functional interpretation for most of these variants is yet to be discovered, but the detailed account of each candidate gene is beyond the scope of this article and has been covered by previous enlightening reviews ([@B13]; [@B2]). Overall, most of the candidate gene associations displayed small to modest effect sizes and, combined all together, account for a small fraction of the phenotype variability ([@B55]).

Genome-Wide Association Studies {#s4}
===============================

It was only in 2007 that the first large-scale genetic association studies or GWASs have been published with the seminal publication by Fellay et al. that focused mainly on viral load at set point as the main phenotype of interest ([@B15]). These large-scale genomic studies have relied on genotyping chips targeting simultaneously hundreds of thousands to millions of specific genetic markers called single nucleotide polymorphisms (SNPs), the most frequent polymorphisms in the human genome, that can be rapidly and easily genotyped. In contrast to the candidate gene strategy, this approach measures and analyzes gene variants across the whole human genome in an effort to identify common genetic risk factors in the population without any biological hypothesis *apriori*. Since the 2007 publication, GWASs have taken the place of candidate gene studies in AIDS. More than 20 GWASs focusing on various phenotypes and cohorts have been published, and [**Table 1**](#T1){ref-type="table"} summarizes these studies with their main characteristics (see also ([@B44])): date of the publication, origin of the cohort, size of the cohort, phenotype(s) of interest, genotyping chip type, associated SNP(s), best P-value, possible causing gene(s) involved, and publication reference number.

###### 

GWASs published in the AIDS field since 2007. 5×10^−8^ is the standard threshold for considering an association as significant in a GWAS, and the significant ones in the table are in bold.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication year   Discovery sample origin                           Discovery sample size                                                        Reported trait                                      Microarray type                                     Main SNPs               P-value                             Gene(s)                       Reference
  ------------------ ------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------- ----------------------------------- ----------------------------- -----------
  2007               European                                          486                                                                          HIV-1 viral set point                               Illumina HumanHap550                                rs239502, rs9264942     **9.36×10^−12^**, **3.77×10^−9^**   *HLA-B\*5701*                 ([@B15])

  2009               European                                          2362                                                                         HIV-1 control (elite and viremic)                   Illumina HumanHap550, Illumina Human1M              rs239502, rs9264942     **5×10^−35^**, **6×10^−32^**        *HCP5/HLA-B\*5701*, *HLA-C*   ([@B14])

  2009               European                                          1071                                                                         AIDS progression                                    Illumina HumanHap550, Illumina Human1M              rs9264942, rs2395029    **6×10^−12^**, **1×10^−11^**        *HLA-C*,\                     ([@B14])
                                                                                                                                                                                                                                                                                                                        *HCP5/HLA-B\*5701*            

  2009               European                                          85 rapid progressors HIV(+), 1,352 CTR HIV(−)                                AIDS progression                                    Illumina HumanHap300                                rs4118325               6×10^−7^                            *PRMT6*                       ([@B40])

  2009               European                                          275 non-progressors HIV(+), 1,352 CTR HIV(−)                                 AIDS progression                                    Illumina HumanHap300                                rs2395029               **6.79×10^−10^**, **6.79×10^−8^**   *HCP5/HLA-B\*5701*            ([@B43])

  2010               European                                          156                                                                          HIV-1 progression                                   Affymetrix Human Mapping 500K                       rs17762192              6.23×10^−7^                         *PROX1-AS1*                   ([@B22])

  2010               African American or Afro-Caribbean                515                                                                          HIV-1 viral set point                               Illumina HumanHap1M, HumanHap1M-Duo, HumanHap550K   rs454422                1.46×10^−6^                         *MCM8*                        ([@B60])

  2010               European                                          1712                                                                         HIV-1 control                                       Illumina HumanHap650Y                               rs9264942, rs4418214    **6.3×10^−16^**                     *HLA-C*, *MICA*               ([@B27])

  2010               African American or Afro-Caribbean                677                                                                          HIV-1 control                                       Illumina HumanHap650Y                               rs2523608               **3.7×10^−15^**                     *-*                           ([@B27])

  2010               Sub-Saharan African                               848 high-risk HIV(−), 531 HIV(+)                                             HIV-1 susceptibility                                Illumina Human1M or 1M-Duo                          rs842304                3.97×10^−6^                         *-*                           ([@B61])

  2010               Sub-Saharan African                               100 HIV(+) infants, 126 HIV(−)                                               HIV susceptibility (mother-to-child transmission)   Illumina HumanHap650Y                               rs12306                 3.92×10^−5^                         *WSB1*                        ([@B31])

  2011               European                                          191                                                                          HIV-1 replication *invitro*                         Illumina Human610-Quad                              rs12483205              2.16×10^−5^                         *DYRK1A*                      ([@B3])

  2011               Sub-Saharan African, African unspecified          302 high-risk HIV(−), 496 HIV(+)                                             HIV-1 susceptibility                                Illumina HumanHap1M-Duo                             rs3745760               7.83×10^−7^                         *GLTSCR1*                     ([@B45])

  2011               Sub-Saharan African, African unspecified          403                                                                          HIV-1 viral set point                               Illumina HumanHap1M-Duo                             rs13111989              2.15×10^−7^                         *VEGFC*                       ([@B45])

  2011               European                                          755                                                                          AIDS progression                                    Affymetrix Human Array 6.0                          rs11884476              **3.37×10^−9^**                     *PARD3B*                      ([@B73])

  2011               European                                          404                                                                          HIV-1 progression                                   Illumina HumanHap300                                rs1523635               3.5×10^−6^                          *AGR3*                        ([@B76])

  2013               European                                          430 high-risk HIV(−) and 765 HIV(+)                                          HIV-1 susceptibility                                Illumina Human1M or 1M-Duo                          \-                      \-                                  *-*                           ([@B37])

  2013               European                                          6,334 HIV-1(+), 7,247 HIV-1(−)                                               HIV-1 susceptibility                                Meta-analysis/imputation                            \-                      \-                                  *-*                           ([@B52])

  2015               African American or Afro-Caribbean and European   628 high-risk HIV(−) vs. 1,376 HIV(+), 327 high-risk HIV(−) vs. 805 HIV(+)   HIV-1 susceptibility                                Illumina HumanOmni1-Quad                            rs4878712               4.38×10^−8^, 7.78×10^−4^            *CD33*, *FRMPD1*              ([@B30])

  2015               European                                          6,315                                                                        HIV-1 viral set point                               Meta-analysis/imputation                            rs59440261, rs1015164   **2×10^−83^**, **1.5×10^−19^**      *HLA-B\*5701*, *CCRL2*        ([@B51])

  2015               East Asian                                        538                                                                          HIV-1 viral set point                               Illumina Human660W-Quad                             rs2442719               8×10^−7^                            *HLA-B*                       ([@B79])

  2017               Sub-Saharan Africans                              556                                                                          AIDS progression                                    Illumina HumanOmni2.5M                              rs2535307               3.72×10^−7^                         *HCG22*                       ([@B80])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CTR, controls

The following major conclusions can be underlined from these GWA studies:

1.  One signal was repeatedly replicated in several cohorts (of European descent) both for the viral load phenotype and also for the non-progression phenotype: rs2395029, an SNP in the *HCP5* gene within the *MHC* region, which was described in nearly full linkage disequilibrium (LD) with the *HLA*-B\*5701 allele ([@B15]; [@B9]; [@B43]; [@B52]; [@B53]). This *HLA* allele could be critical for the destruction of infected cells *via* a yet-unidentified CD8 T-cell epitope, but we cannot exclude a role for other polymorphisms in the *HLA* region and possibly outside of the class I *HLA* genes, with relevant genes highlighted through LD such as *MICB* and *TNF* ([@B36]). Similarly, in African Americans, the *HLA*-B\*5703 allele was demonstrated to be important for viral control ([@B60]; [@B54]; [@B53]). Beyond B\*57 alleles, *HLA* seems to play a major role in viral control, as another SNP located 35 kb upstream of *HLA-C* was also identified in Europeans ([@B43]; [@B53]). This −35 kb SNP was correlated with higher HLA-C cell surface expression ([@B72]), which can be regulated through microRNA (miRNA) binding ([@B36]) and through the binding of the Oct1 transcription factor ([@B77]).

2.  In 2011, the HIV/AIDS research community conducted a massive effort to bring together their genomic data in order to gain statistical power of detection. This collaborative effort, named the International Consortium for the Genetics of HIV-1 (ICGH), gathered up to 6,300 HIV-infected individuals and 7,200 HIV-uninfected controls who were genotyped on various Illumina or Affymetrix platforms. A first publication emerged from this consortium in 2013; it focused on HIV-1 acquisition and confirmed the major role of *CCR5*-Delta32 in resistance to infection but did not identify any additional common genetic variant ([@B52]). A second study was published 2 years later on viral control and disease progression and confirmed the complementary roles of *CCR5* locus variants and of *HLA* genetic variants coding for amino acids in the peptide binding grooves of HLA-A and HLA-B ([@B51]). In spite of the large sample size, no other locus reached genome-wide significance. These reports conclude that future genetic studies should target other classes of genetic variants (e.g., low or rare frequency), non-European populations, and well-defined homogeneous phenotypes ([@B51]).

3.  In addition, the numerous GWASs have identified novel candidate genes, which all deserve further exploration, notably the ones that reached genome-wide significance (see [**Table 1**](#T1){ref-type="table"}). In particular, a genetic variant within the *CXCR6* gene was associated with long-term non-progression in four independent cohorts ([@B42]). This signal was only identified in individuals without sustained viral control, which explains why it was not highlighted in the consortium that mainly focused on viral control. Finally, the absence of replication for many other signals presented in [**Table 1**](#T1){ref-type="table"} does not discount their scientific interest but complicates their biological interpretation.

Next-Generation Sequencing Studies {#s5}
==================================

GWASs rely on common SNPs (typically \>1% in the population) and hardly take into account the possible effect of rare variants or other classes of genetic polymorphisms such as indels or copy number variants that can also significantly impact disease outcome. To investigate the impact of such variants, we first focused on low-frequency SNPs (\<5%) in our progression GWASs and identified the gene *RICH2* associated with non-progression, which interacts with BST-2, a major known HIV restriction factor ([@B39]). Later, several studies based on next-generation sequencing (NGS) have emerged. Due to the high cost of such studies and to maximize statistical power of detection, these screenings have targeted coding variants (exome) and patients with very specific and extreme disease outcome. To our knowledge, only one publication has emerged from these studies ([@B53]), which focused on 1,327 subjects, many of whom were elite and viral controllers. In spite of the significant number of patients studied, only variants in the *HLA* region came out, and this study suggested that exonic variants with large effect sizes are unlikely to have a major contribution to host control of HIV infection ([@B53]).

Functional Genomic Screenings {#s6}
=============================

Systematic inactivation of gene expression through siRNA and small hairpin RNA (shRNA) offers a unique chance to identify host genes required for HIV replication. In large-scale studies, authors used siRNAs ([@B5]; [@B35]; [@B87]) or shRNAs ([@B83]) to silence *invitro* most known genes one by one in HIV permissive cell lines. These screenings identified 273 ([@B5]), 213 ([@B35]), 311 ([@B87]), and 252 ([@B83]) HIV host dependency factors, respectively, for a total of 842 putative candidates. However, the overlap between the different studies was very low, suggesting low reproducibility and/or high false positive, which might not be surprising considering the different experimental models (cell lines, HIV strains, and measurement modes of HIV replication). Overall, these studies still provide an interesting list of candidate cellular factors and pathways potentially implicated in HIV-1 replication that could be considered as relevant targets for drug development.

The development of the CRISPR--Cas9 technology to screen each gene with a library of single-guided RNA offers a greater sensitivity and specificity than interference based-RNA ([@B78]). A recent report used this technology to screen a CD4 T-cell line and identified five host factors required for HIV replication, including CD4, C-C motif chemokine receptor 5 (CCR5), and activated leukocyte cell adhesion molecule (ALCAM ([@B59]). These factors were further validated in primary human CD4 T-cells and therefore represent major candidates for a therapeutic intervention.

Transcriptomic Studies {#s7}
======================

The first descriptions of transcriptome analysis by DNA microarrays were in cancer in 2002 ([@B63]; [@B74]). In AIDS, the first large-scale transcriptomic study (4,600 transcripts) was published in 2003 ([@B75]). This study analyzed gene expression in HIV-infected CD4 T-cell lines at different time points and revealed the inhibition of genes involved in cell division, transcription, translation, splicing, and also cholesterol biosynthesis ([@B75]). An exon transcriptome microarray analysis of purified HIV-infected cells revealed host cell factors required for viral replication and alternative splicing events ([@B26]). A bioinformatic analysis of HIV-resistant activated CD4 T-cells (due to CD3/CD28 antibodies' co-stimulation) highlighted a few dozen genes critical for resistance or permissivity ([@B81]).

Several microarray studies focused on non-human primate models, such as cynomolgus monkeys ([@B4]) and African green monkeys (non-pathogenic model) vs. rhesus macaques (pathogenic model) ([@B29]). These reports mainly identified a major role for IFN-stimulated genes, as well as a differential expression of some innate genes (such as LPS receptors CD14 and TLR4) and some apoptosis-related genes ([@B4]).

Finally, numerous transcriptome studies explored differential gene expression in HIV-infected individuals. A first report in 2005 claimed to have found ([@B56]) a 10-gene signature for HIV-1 serostatus and a 6-gene signature for subjects experiencing a CD4+ T-cell decrease ([@B56]). The genes identified were primarily linked with immune response and apoptosis, mitochondrial function, and RNA binding (downregulated in subjects with better prognosis) ([@B56]). A study focusing on HIV-1--resistant individuals ([@B24]) found a set of 185 HIV-1 resistance genes, suggesting a major role for *nef* in disease pathogenesis, and among them pointed out 29 potential targets for AIDS prevention or therapy ([@B24]). By comparing the complementary DNA (cDNA) profiles of CD3+ T-cells in long-term non-progressors vs. medium progressors ([@B67]), 325 genes appeared over-expressed in regular progressors (from DNA replication, cell cycle, and DNA damage pathways), vs. 136 over-expressed genes in long-term non-progressors (from cytokine--cytokine receptor interaction and negative control of apoptosis pathways) ([@B67]). The transcriptome comparison of CD4+ T-cells and CD8+ T-cells from rapid progressors, viremic non-progressors, and elite controllers showed a lower expression of IFN-stimulated genes and an upregulation of *CASP1*, *CD38*, *LAG3*, *TNFSF13B*, *SOCS1*, and *EEF1D* genes in viremic non-progressors ([@B65]). Finally, a transcriptomic screening also targeted miRNA expression profiles in peripheral blood mononuclear cell (PBMC) from rapid and chronic progressors and identified five downregulated miRNAs in rapid progressors that all converged to the apoptosis pathway ([@B86]).

Proteomic and Epigenomic Studies {#s8}
================================

Some proteomic studies have also been performed, but they were not very reproducible, as indicated in a recent review by [@B12]. To our knowledge, few epigenomic studies have been published to date in HIV/AIDS. One Korean group performed two chromatin immunoprecipitation sequencing (ChIP-seq) analyses in HIV latently infected CD4 T-cell lines to investigate the impact of H3K4me3 and H3K9ac histone modifications on latency. They revealed several potential candidate genes, including *NFIX*, tumor necrosis factor (TNF) receptor association factor 4 (*TRAF4*), and cell cycle regulating genes such as *CDKN1A* (p21) and *CCND2* ([@B58]; [@B34]). Finally, the blood DNA methylation signatures of HIV-infected and uninfected subjects were compared through an epigenome-wide association study (EWAS), which highlighted a down-methylation of *NLC5* promoter in HIV-infected subjects ([@B85]). This host gene encodes a key regulator of class I *HLA* gene expression and confirms the major role of the *MHC* locus in HIV viral control. Interestingly, *NLC5* promoter and additional *MHC* clusters also appeared differentially methylated in HIV--Hepatitis C virus (HCV) co-infected subjects ([@B84]), emphasizing the importance of inflammation-related genes in the course of HIV infection. Overall, these studies are promising and underline the need for additional large-scale epigenetic studies in order to better capture the breadth of host--HIV complex interactions.

Conclusion and Future Directions {#s9}
================================

In this review, we have presented numerous large-scale genomic and transcriptomic analyses that have taken place in the AIDS field, which are the consequences of the progress in molecular biology and biochemistry technologies. One can see that a huge research effort has been dedicated to genetic association studies, and this is logical since this experimental approach deals with real *invivo* data, i.e., cohorts of patients and HIV-1 infection *invivo*. Nevertheless, it was slightly surprising to observe that the main signals found by GWAS, in the *HLA* and *CCR5* loci, had already been identified by previous candidate gene approaches. This apparent limitation could be explained by the yet-unidentified role of other polymorphisms such as copy number variations (CNVs) or interacting gene variants. It could also be explained by the statistical constraints (such as stringent multiple testing corrections) that limit the use of genetic association data (numerous false negatives) and the overall low number of samples at stake (a few thousands) compared to other human diseases such as diabetes or obesity (hundreds of thousands) ([@B69]; [@B18]). In light of the available biological information provided by the other large-scale studies such as transcriptomic or functional genomic studies presented in this review, it appears important to reanalyze the genomic data by integrating biological information in order to enhance the genetic association results. For instance, our group has successfully implemented such approaches by pre-selecting relevant SNPs defined either by their low frequency ([@B39]) or by their functional impact as potential expression quantitative trait loci (eQTLs) ([@B71]). More generally, there are several methods for data integration, the first one being to cross-check the results obtained by one method through another, for instance, using GWAS to identify SNPs with low P-values, even non-significant, and then using transcriptomics to pick genes that are differentially expressed in a relevant cell type or tissue. By combining two (or more) methods, researchers can zoom in on specific genes of high interest. This has been implemented with the development of PrediScan ([@B19]). Another example of cross-checking is the results obtained by metabolome analysis and GWAS in which the researchers have found that metabolites present at high levels in the blood of some subjects are highly correlated with specific variants present in the genes of enzymes involved in their metabolism ([@B25]). Other methods of data integration rely on rescuing genes by correlating signals not only at the gene level but also at the pathway level: for instance, one can suspect that if a gene X in a biological pathway is important for a clinical phenotype, the genes present upstream in the biological pathway may impact this gene X expression and, as a consequence, also become targets of interest. One will thus have to look for cross-checks at the level of pathways ([@B8]). Importantly, it is essential for data integration to perform all these cross-checks in a smart and automated manner. Finally, more sophisticated statistical approaches have recently emerged outside of the HIV field, such as the Bayesian method for data integration ([@B33]; [@B62]; [@B16]; [@B82]; [@B28]). These new methods are yet to be implemented in the relatively small HIV/AIDS cohorts but might reveal novel underlying physiopathological mechanisms.

With the massive research effort to fight AIDS, this has been a true field of experimentation and development for novel technologies. A first challenge is now the cross-usage of all this information gathered from so many large-scale studies, to transform this "gold mine" into diagnostic or therapy strategies to fight AIDS, and the same integration of omics big data should of course take place also for other human diseases. This systems biology challenge has not yet been met. A second challenge is to pursue the exploration of alternative technologies such as epigenomics or proteomics to derive more understanding of HIV-1 molecular pathogenesis. We hope that the AIDS field will remain a "cultural" leader for research progress in order to fully understand the molecular mechanisms at stake in HIV-1 infection and AIDS and allow the rationale development of diagnostic and therapeutic strategies to finally tackle the HIV-1 virus.
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